浏览全部资源
扫码关注微信
Research Progress on Effect of Hypoglycemic Mechanism of Berberine in Treatment of Type 2 Diabetes Mellitus
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 22, Pages: 219-226(2019)
- 作者机构：
1.上海中医药大学 科技实验中心，上海 201203；
2.上海中医药大学 教学实验中心，上海 201203
- 作者简介：
- 基金信息：
DOI：10.13422/j.cnki.syfjx.20191806
CLC： R2-0; R22; R285.5; R284.1Published：20 November 2019，
Published Online：04 June 2019，
Received：11 March 2019，
- 稿件说明：
扫 描 看 全 文
Ai-yun LI, Jing YANG, Xin-yu ZHANG, et al. Research Progress on Effect of Hypoglycemic Mechanism of Berberine in Treatment of Type 2 Diabetes Mellitus. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(22):219-226(2019)
Ai-yun LI, Jing YANG, Xin-yu ZHANG, et al. Research Progress on Effect of Hypoglycemic Mechanism of Berberine in Treatment of Type 2 Diabetes Mellitus. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(22):219-226(2019) DOI： 10.13422/j.cnki.syfjx.20191806.
摘要
近年来，随着人们生活水平的提高，2型糖尿病的发病率全球性增加，严重威胁人类健康。2型糖尿病是一种以高血糖为主要特征的渐进性代谢疾病。常规治疗包括控制饮食、使用口服降血糖药物或皮下注射胰岛素等。目前，除了化学药品如二甲双胍和噻唑烷二酮类以外，研究发现天然药物及传统中药复方具有温和的降糖作用或胰岛素增敏作用，还能够改善糖尿病并发症，在维持血糖稳态方面具有一定优势。小檗碱主要是从药用植物黄连中提取分离的一种具有多种药理活性的异喹啉类生物碱。目前认为小檗碱是治疗2型糖尿病最具前景的天然降糖药物之一。小檗碱降血糖的机制较为引人关注，该文就近年来小檗碱降血糖的药理作用机制研究进展进行综述，其中包括改善胰岛素抵抗、促进胰岛素及胰高血糖素样肽-1(GLP-1)的分泌、抑制肝脏糖异生、减少肠道细胞对糖的摄取吸收、抑制氧化应激及炎性反应、调控肠道菌群等。阐明小檗碱降血糖作用机制有助于更好地认识小檗碱治疗2型糖尿病的药理作用，并为小檗碱治疗2型糖尿病的合理应用提供依据。
Abstract
In recent years
type 2 diabetes mellitus (T2DM) has an increasing incidence worldwide along with the improvement of people's living standards
and emerged as a serious threat to human health. T2DM is a progressive metabolic disease characterized by hyperglycemia
and its routine therapies include diet control
the use of oral hypoglycemic drugs or subcutaneous injection with insulin. At present
in addition to chemical drugs
such as metformin and thiazolidinediones
researchers have also found that natural medicines and traditional Chinese medicine compounds have mild hypoglycemic and insulin sensitizing effects. Besides
these drugs also have effects in alleviating diabetes complications and maintaining glucose homeostasis. Berberine is an isoquinoline alkaloid mainly isolated from Coptis chinensis with multiple pharmacological activities. Currently
berberine is considered to be one of the most promising natural hypoglycemic agents for the treatment of type 2 diabetes mellitus. However
mechanisms of the hypoglycemic effect of berberine were complex. In this review
we summarized the pharmacological mechanisms of hypoglycemic effect of berberine
including improving insulin resistance
promoting insulin and glucagon-like peptide-1 (GLP-1) secretion
inhibiting hepatic gluconeogenesis
reducing glucose absorption in intestinal cells
suppressing oxidative stress and inflammation and modulating gut microbiota
clarified the mechanisms of hypoglycemic effect of berberine could help to understand the pharmacology of berberine in the treatment of diabetes mellitus and provided evidence for rational application of berberine in the treatment of type 2 diabetes.
关键词
小檗碱2型糖尿病降血糖作用研究进展
Keywords
berberinetype 2 diabeteshypoglycemic activityresearch progress
references
WANG Z, WANG J, CHAN P. Treating type 2 diabetes mellitus with traditional Chinese and Indian medicinal herbs [J].Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/343594http://doi.org/10.1155/2013/343594.
El-Kaissi S, Sherbeeni S. Pharmacological management of type 2 diabetes mellitus: an update [J].Curr Diabetes Rev, 2011, 7(6): 392-405.
HUNG H Y, QIAN K, Morris-Natschke S L, et al. Recent discovery of plant-derived anti-diabetic natural products [J].Nat Prod Rep, 2012, 29(5): 580-606.
YIN J, ZHANG H, YE J. Traditional Chinese medicine in treatment of metabolic syndrome [J].Endocr Metab Immune Disord Drug Targets, 2008, 8(2): 99-111.
Tzeng T F, Liou S S, LIU I M. The selected traditional Chinese medicinal formulas for treating diabetic nephropathy: perspective of modern science [J].J Tradit Complement Med, 2013, 3(3): 152-158.
Vuddanda P R, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities [J].Expert Opin Investig Drugs, 2010, 19(10): 1297-1307.
Watson R T, Kanzaki M, Pessin J E. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes [J].Endocr Rev, 2004, 25(2): 177-204.
XI C, Miyaki K, Ikeda S, et al. ociation of GLUT4 gene variants with HbA1c level in Japanese men [J].Endocr J, 2012, 59(8): 677-684.
ZHANG Y, YE J. Mitochondrial inhibitor as a new class of insulin sensitizer [J].Acta Pharm Sin B, 2012, 2(4): 341-349.
Shulman G I. Cellular mechanisms of insulin resistance [J].J Clin Invest, 2000, 106(2): 171-176.
Hwang J T, Kwon D Y, Yoon S H. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols [J].N Biotechnol, 2009, 26(1/2): 17-22.
Kahn B B, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism [J].Cell Metab, 2005, 1(1): 15-25.
Lee Y S, Kim W S, Kim K H, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states [J].Diabetes, 2006, 55(8): 2256-2264.
Turner N, LI J Y, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action [J].Diabetes, 2008, 57(5): 1414-1418.
Kim S H, Shin E J, Kim E D, et al. Berberine activates GLUT1-mediated glucose uptake in 3T3-L1 adipocytes [J].Biol Pharm Bull, 2007, 30(11): 2120-2125.
KONG W J, ZHANG H, SONG D Q, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression [J].Metabolism, 2009, 58(1): 109-119.
LIU L Z, Cheung S C, LAN L L, et al. Berberine modulates insulin signaling transduction in insulin-resistant cells [J].Mol Cell Endocrinol, 2010, 317(1/2): 148-153.
XIE X, LI W, LAN T, et al. Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway [J].Endocr J, 2011, 58(9): 761-768.
YIN J, XING H, YE J. Efficacy of berberine in patients with type 2 diabetes mellitus [J].Metabolism, 2008, 57(5): 712-717.
ZHOU J, ZHOU S, TANG J, et al. Protective effect of berberine on beta cells in streptozotocin-and high-carbohydrate/high-fat diet-induced diabetic rats [J].Eur J Pharmacol, 2009, 606(1/3): 262-268.
ZHOU L, WANG X, SHAO L, et al. Berberine acutely inhibits insulin secretion from β-cells through 3′, 5′-cyclic adenosine 5′-monophosphate signaling pathway [J].Endocrinology, 2008, 149(9): 4510-4518.
SHEN N, HUAN Y, SHEN Z F. Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell [J].Eur J Pharmacol, 2012, 694(1/3): 120-126.
Rouillé Y, Martin S, Steiner D F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide [J].J Biol Chem, 1995, 270(44): 26488-26496.
Ranganath L R. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 [J].J Clin Pathol, 2008, 61(4): 401-409.
YU Y, LIU L, WANG X, et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies [J].Biochem Pharmacol, 2010, 79(7): 1000-1006.
LU S S, YU Y L, ZHU H J, et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats [J].J Endocrinol, 2009, 200(2): 159-165.
YU Y, HAO G, ZHANG Q, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways [J].Biochem Pharmacol, 2015, 97(2): 173-177.
Derosa G, Maffioli P, Cicero A F. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials [J].Expert Opin Biol Ther, 2012, 12(8): 1113-1124.
Yoon J C, Puigserver P, CHEN G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 [J].Nature, 2001, 413(6852): 131-138.
Miller R A, CHU Q, XIE J, et al. Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP [J].Nature, 2013, 494(7436): 256-260.
Ozcan L, Wong C C, LI G, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity [J].Cell Metab, 2012, 15(5): 739-751.
Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction [J].Nature, 2003, 423(6939): 550-555.
Kim D K, Kim Y H, Hynx D, et al. PKB/Akt phosphorylation of ERRγ contributes to insulin-mediated inhibition of hepatic gluconeogenesis [J].Diabetologia, 2014, 57(12): 2576-2585.
Hirota k, Daitoku H, Matsuzaki H, et al. Hepatocyte nuclear factor-4 is a novel downstream target of insulin via FKHR as a signal-regulated transcriptional inhibitor [J].J Biol Chem, 2003, 278(15): 13056-13060.
Shaw R J, Lamia K A, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin [J].Science, 2005, 310(5754): 1642-1646.
JIANG S J, DONG H, LI J B, et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats [J].World J Gastroenterol, 2015, 21(25): 7777-7785.
ZHANG M, LV X, LI J, et al. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis [J].Mol Cell Endocrinol, 2012, 363(1/2): 122-130.
XIA X, YAN J, SHEN Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis [J].PLoS One, 2011, 6(2): e16556.
LI Z Y, XI Y, ZHU W N, et al. Positive regulation of hepatic miR-122 expression by HNF4α [J].J Hepatol, 2011, 55(3): 602-611.
WANG Z Q, LU F E, LENG S H, et al. Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity [J].World J Gastroenterol, 2008, 14(39): 6004-6011.
WEI S, ZHANG M, YU Y, et al. Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4α miR122 pathway [J].PLoS One, 2016, 11(3): e0152097.
Berger J, Moller D E. The mechanisms of action of PPARs [J].Annu Rev Med, 2002, 53: 409-435.
ZHOU J Y, ZHOU S W, ZHANG K B, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats [J].Biol Pharm Bull, 2008, 31(6): 1169-1176.
Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation [J].Biochim Biophys Acta, 1996, 1302(2): 93-109.
YE M, FU S, PI R, et al. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research [J].J Pharm Pharmacol, 2009, 61(7): 831-837.
ZOU L, LI R, WANG P, et al. The study of absorption kinetics of berberine based on portal vein in rat, and the influence of verapamil and borneol to its absorption ability by UHPLC method [J].Eur J Drug Metab Pharmacokinet, 2014, 39(3): 165-171.
PAN G Y, HUANG Z J, WANG G J, et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption [J].Planta Med, 2003, 69(7): 632-636.
LIU L, DENG Y, YU S, et al. Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats [J].Pharmazie, 2008, 63(5): 384-388.
LIU L, YU Y L, YANG J S, et al. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study [J].Naunyn Schmiedebergs Arch Pharmacol, 2010, 381(4): 371-381.
FENG R, SHOU J W, ZHAO Z X, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota [J].Sci Rep, 2015, doi: 10.1038/srep12155http://doi.org/10.1038/srep12155.
Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome [J].J Clin Invest, 2004, 114(12): 1752-1761.
Bonnefont-Rousselot D. Glucose and reactive oxygen species [J].Curr Opin Clin Nutr Metab Care, 2002, 5(5): 561-568.
Evans J L, Goldfine I D, Maddux B A, et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction [J].Diabetes, 2003, 52(1): 1-8.
Moghaddam H K, Baluchnejadmojarad T, Roghani M, et al. Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats [J].Mol Neurobiol, 2014, 49(2): 820-826.
ZHOU J Y, ZHOU S W. Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver [J].Fitoterapia, 2011, 82(2): 184-189.
CHENG F, WANG Y, LI J, et al. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans [J].Int J Cardiol, 2013, 167 (3): 936-942.
YANG Q H, HU S P, ZHANG Y P, et al. Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats [J].Chin J Integr Med, 2011, 17(3): 205-211.
Hsu Y Y, CHEN C S, WU S N, et al. Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells [J].Eur J Pharm Sci, 2012, 46(5): 415-425.
Gratas-Delamarche A, Derbré F, Vincent S, et al. Physical inactivity, insulin resistance, and the oxidative-inflammatory loop [J].Free Radic Res, 2014, 48(1): 93-108.
Shinozaki S, Choi C S, Shimizu N, et al. Liver-specific inducible nitric-oxide synthase expression is sufficient to cause hepatic insulin resistance and mild hyperglycemia in mice [J].J Biol Chem, 2011, 286(40): 34959-34975.
JIANG Q, LIU P, WU X, et al. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway [J].Mol Cell Endocrinol, 2011, 331(1): 34-40.
Hsu Y Y, Tseng Y T, Lo Y C. Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth [J].Toxicol Appl Pharmacol, 2013, 272(3): 787-796.
Donath M Y. Targeting inflammation in the treatment of type 2 diabetes: time to start [J].Diabetes Obes Metab, 2013, doi: 10.1038/nrd4275http://doi.org/10.1038/nrd4275.
WANG Z S, LU F E, XU L J, et al. Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells [J].Acta Pharmacol Sin, 2010, 31(5): 578-584.
Cani P D, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice [J].Diabetes, 2008, 57(6): 1470-1481.
Hotamisligil G S. Inflammation and metabolic disorders [J].Nature, 2006, 444(7121): 860-867.
Cani P D, Delzenne N M. The role of the gut microbiota in energy metabolism and metabolic disease [J].Curr Pharm Des, 2009, 15(13): 1546-1558.
Iwazaki R S, Endo E H, Ueda-Nakamura T, et al. In vitro antifungal activity of the berberine and its synergism with fluconazole [J].Antonie Van Leeuwenhoek, 2010, 97(2): 201-205.
YAN D, JIN C, XIAO X H, et al. Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry [J].J Biochem Biophys Methods, 2008, 70(6): 845-849.
ZHANG X, ZHAO Y, ZHANG M, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats [J].PLoS One, 2012, 7(8): e42529.
Ley R E, Turnbaugh P J, Klein S, et al. Microbial ecology: human gut microbes associated with obesity [J].Nature, 2006, 444(7122): 1022-1023.
Dibaise J K, ZHANG H, Crowell M D, et al. Gut microbiota and its possible relationship with obesity [J].Mayo Clin Proc, 2008, 83(4): 460-469.
贺娅莎，王彦．小檗碱对2型糖尿病小鼠肠道菌群影响的相关研究[J]．糖尿病新世界，2015，8(128)：42-43．
顾融融．小檗碱对2型糖尿病小鼠肠道菌群影响的相关研究[J]．临床医药文献电子杂志，2017，4(61)：11885．
Domadia P N, Bhunia A, Sivaraman J, et al. Berberine targets assembly of Escherichia coli cell division protein FtsZ [J].Biochemistry, 2008, 47(10): 3225-3234.
ZHANG X, ZHAO Y, XU J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet induced obesity in rats [J].Sci Rep, 2015, doi: 10.1038/srep14405http://doi.org/10.1038/srep14405.
0
Views
8
下载量
5
CSCD
- L-PDFDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Postal code：100700
- Tel：010-84076882 Email：syfjx_2010@188.com
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
